Objectıve: Heart rate recovery (HRR) is influenced by autonomic function. Percutaneous coronary intervention (PCI) improves cardiac symptoms and reduces morbidity and mortality in coronary artery disease (CAD). We aimed to investigate the effect of PCI on HRR and the relationship of HRR index with the degree of coronary stenosis in patients with severe stable CAD. Methods: The treatment group (TG) consisted of 70 severe stable CAD patients treated with PCI, and the control group (CG) with 62 minimal CAD patients, who were not treated with PCI. All participants underwent exercise test both at baseline and 3 months after coronary angiography (CAG)/PCI. HRR was defined as a change in HR from peak exercise to 1 minute after exercise. HRR index was described as the percentage change in HRR from 3 months after CAG/PCI to baseline. Results: HRR was lower in the TG at baseline (p<0.05), and showed a significant increase after 3 months, when compared with baseline data (p<0.001). In the TG, while HRR was inversely correlated with the number of diseased coronary artery at baseline (r¼-0.418, p<0.001), this correlation was not observed after 3 months (p¼0.602). HRR index was higher in the TG than the CG (p<0.001). No associations were found between HRR (p¼0.136), HRR index (p¼0.703) and the severity of coronary stenosis. Patients who had multiple vessels treated, had the highest HRR index. Conclusıon: Our results showed that PCI is associated with improved HRR in proportion to the number of coronary vessels treated in severe stable CAD. In addition to standard exercise test data, the use of HRR may be beneficial for the risk stratification and follow-up of those patients. Purpose: Galectin-3 (Gal-3) is a beta-galactoside-binding lectin expressed by activated macrophages and involved in crucial steps of atherogenesis. Circulating levels of Gal-3 has emerged as a novel informative biomarker in patients with acute STsegment elevation myocardial infarction and congestive heart failure. The aim of this study is to investigate clinical relevance of circulating Gal-3 levels in patents who underwent coronary angiography with suspected CAD. Methods: One hundred and five consecutive patients (49 females, 56 males; mean age 59.7 years) who underwent first-time diagnostic coronary angiography from March 2013 to June 2013 were included in this study. Peripheral blood samples were taken from antecubital vein for determination of serum Gal-3 concentrations before coronary angiography. Serum Gal-3 levels were determined by a commercially available sandwich enzyme-linked immunosorbent assay kit (catalog no: BMS279/2, Bender medSystems GmbH, Vienna, Austria). The measuring range of the assay 0.39-25 ng/ mL. Intra-assay and inter-assay coefficients of variant were <5%. Patients were divided into three groups according to degree of coronary stenosis: normal coronary arteries (26 patients, group 1), non-significant (<50%) stenosis (47 patients, group 2), and critical (>50%) stenosis (32 patients, group 3). The severity and extent of CAD was evaluated by calculation of vessel and Gensini scores. Results: Demographic and clinical characteristics of the patients were listed in Table  1 . Patients with CAD (groups 2 and 3) were mostly males and they were significantly older in respect to group 1 (p<0.01). Serum Gal-3 levels were highest in group 3 (19.16 AE 1.37 ng/mL), and also significantly elevated in group 2 compared to group 1 (13.53 AE 2.10 vs 5.69 AE 2.34 ng/mL; p<0.001). Serum Gal-3 levels were correlated with the number of diseased vessels and Gensini score (Figure 1) . Conclusıons: We demonstrated that serum levels of Gal-3 is a useful biomarker of coronary atherosclerotic involvement in patients who underwent first time diagnostic coronary angiography with suspicion of CAD. Objectıve: Sufficient coronary collateral circulation (CCC) protects myocardial tissue against ischemia in patients with coronary chronic total occlusion (CTO). In this study, we aimed to investigate whether there is an association between serum gglutamyl transferase (GGT) levels and development of CCC in patients with coronary CTO. Methods: A total of 203 patients with CTO at coronary angiography were included in this study. On the day of admission to the hospital, blood samples were taken and GGT levels were analyzed for all patients. Development of collateral circulation was graded according to the Rentrop classification after coronary angiography. Then, patients were divided into two groups on the basis of CCC grades: group 1 included 99 patients (49%) with poorly developed CCC, and group 2 included 104 patients (51%) with well-developed CCC. Results: Patients with poorly developed CCC had significantly higher serum GGT levels compared with those with well-developed CCC, (66.5AE16 vs. 51.8AE10 U/l, p<0.0001). Correlation analysis showed an inverse correlation between GGT levels and the Rentrope score (r¼-0.579, p<0.001). Logistic regression analysis showed that GGT level was an independent predictor of poorly developed CCC (odds ratio 0.92, 95% confidence interval 0.90-0.94; p<0.001). Conclusıon: Increased serum GGT levels independently predict poorly developed CCC in patients with coronary CTO. Our results show that GGT is a simple and readily available marker for sufficiency of CCC in patients with CTO. 
Purpose: Galectin-3 (Gal-3) is a beta-galactoside-binding lectin expressed by activated macrophages and involved in crucial steps of atherogenesis. Circulating levels of Gal-3 has emerged as a novel informative biomarker in patients with acute STsegment elevation myocardial infarction and congestive heart failure. The aim of this study is to investigate clinical relevance of circulating Gal-3 levels in patents who underwent coronary angiography with suspected CAD. Methods: One hundred and five consecutive patients (49 females, 56 males; mean age 59.7 years) who underwent first-time diagnostic coronary angiography from March 2013 to June 2013 were included in this study. Peripheral blood samples were taken from antecubital vein for determination of serum Gal-3 concentrations before coronary angiography. Serum Gal-3 levels were determined by a commercially available sandwich enzyme-linked immunosorbent assay kit (catalog no: BMS279/2, Bender medSystems GmbH, Vienna, Austria). The measuring range of the assay 0.39-25 ng/ mL. Intra-assay and inter-assay coefficients of variant were <5%. Patients were divided into three groups according to degree of coronary stenosis: normal coronary arteries (26 patients, group 1), non-significant (<50%) stenosis (47 patients, group 2), and critical (>50%) stenosis (32 patients, group 3). The severity and extent of CAD was evaluated by calculation of vessel and Gensini scores. Results: Demographic and clinical characteristics of the patients were listed in Table  1 . Patients with CAD (groups 2 and 3) were mostly males and they were significantly older in respect to group 1 (p<0.01). Serum Gal-3 levels were highest in group 3 (19.16 AE 1.37 ng/mL), and also significantly elevated in group 2 compared to group 1 (13.53 AE 2.10 vs 5.69 AE 2.34 ng/mL; p<0.001). Serum Gal-3 levels were correlated with the number of diseased vessels and Gensini score (Figure 1 ). Conclusıons: We demonstrated that serum levels of Gal-3 is a useful biomarker of coronary atherosclerotic involvement in patients who underwent first time diagnostic coronary angiography with suspicion of CAD. Objectıve: Sufficient coronary collateral circulation (CCC) protects myocardial tissue against ischemia in patients with coronary chronic total occlusion (CTO). In this study, we aimed to investigate whether there is an association between serum gglutamyl transferase (GGT) levels and development of CCC in patients with coronary CTO. Methods: A total of 203 patients with CTO at coronary angiography were included in this study. On the day of admission to the hospital, blood samples were taken and GGT levels were analyzed for all patients. Development of collateral circulation was graded according to the Rentrop classification after coronary angiography. Then, patients were divided into two groups on the basis of CCC grades: group 1 included 99 patients (49%) with poorly developed CCC, and group 2 included 104 patients (51%) with well-developed CCC. Results: Patients with poorly developed CCC had significantly higher serum GGT levels compared with those with well-developed CCC, (66.5AE16 vs. 51.8AE10 U/l, p<0.0001). Correlation analysis showed an inverse correlation between GGT levels and the Rentrope score (r¼-0.579, p<0.001). Logistic regression analysis showed that GGT level was an independent predictor of poorly developed CCC (odds ratio 0.92, 95% confidence interval 0.90-0.94; p<0.001). Conclusıon: Increased serum GGT levels independently predict poorly developed CCC in patients with coronary CTO. Our results show that GGT is a simple and readily available marker for sufficiency of CCC in patients with CTO. Introductıon: Resistin which is derived by the gene of RSTN, belongs to a family cysteine-rich secretory proteins called resistin-like molecules (RELM). It was first characterized in murine models as a hormone associated with obesity and insulin resistance. The increased serum resistin levels are associated with coronary artery disease (CAD) and the risk of cardiovascular (CV) death. Materıal-Method: The study group consisted of 214 patients who underwent coronary angiogram due to stable angina pectoris (SAP) or unstable angina pectoris (USAP) and acute coronary syndrome without ST segment elevation myocardial infarction (NSTEMI) in Istanbul University Institute of Cardiology between December 2011 and December 2012. Blood samples were collected from each patient before coronary angiography; 5 ml of blood were drawn in tubes without anticoagulant. Serum resistin concentrations were measured by using a Human Resistin ELISA assay (Biovendor Company, German). Coronary angiography was performed in all patients. CAD was defined by a plaque in at least 1 major coronary artery. The Gensini score was used to determine the severity and extension of CAD. Results: The serum resistin level in the CAD group (25.50AE15.44 pg/ml) was significantly higher than the control group (17.12AE8.26 pg/ml) (p:0.003). The serum resistin level was 25.39AE13.36 pg/ml in the SAP (p<0.05), 24.95AE18.01 pg/ml in the USAP (p<0.05), 28.16AE16.48 pg/ml in the NSTEMI (p<0.05) groups (Table 1) . Whereas there was no significant difference in the serum resistin levels between NSTEMI, USAP and SAP groups (Table 2 ). There was a positive correlation between Gensini score and serum resistin levels (r¼0.360, p¼0.010) according to Spearman's correlation analysis (Table 3 and Figure 1) .
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Dıscussıon: In our study we found that serum resistin levels were significantly increased in NSTEMI, USAP and SAP when compared with the controls (p:0.003). Reilly et al. reported that serum resistin level was independently associated with coronary artery calcification (CAC). In contrast to our study, Qiao et al. reported serum resistin levels increased with the progress of CAD. In their study serum resistin levels were elevated in the USAP group compared with the SAP group, while the level was highest in AMI (acute myocardial infarction) patients (p<0.05). In our study there was a positive correlation between the Gensini score and serum resistin level. This makes our study different from others because we did not find any study examining the correlation between serum resistin level and Gensini score. In conclusion, we found that there was a relationship between increased serum resistin level and CAD. Also, the serum resistin level was positively correlated with the Gensini score. These observations suggest that resistin may participate in the process of atherosclerosis as an effector molecule of inflammatory reaction. Further investigation is needed to define the role of resistin in patients with CAD. 
